Summary

Treatment strategies for ST-segment elevation myocardial infarction (STEMI) utilize both pharmacological therapies and devices designed to restore coronary blood flow. While these therapies are generally effective, a proportion of patients with STEMI will develop cardiogenic shock, one of the leading causes of inhospital death post MI. Despite an optimal pharmacomechanical approach, revascularization, and hemodynamic support, the mortality in patients with STEMI complicated by cardiogenic shock remains high.